Organ Atrophy Induced by Sorafenib and Sunitinib – Quantitative Computed Tomography (CT) Evaluation of the Pancreas, Thyroid Gland and Spleen
Open Access
- 22 November 2016
- journal article
- Published by Termedia Sp. z.o.o. in Polish Journal of Radiology
- Vol. 81, 557-565
Abstract
BACKGROUND:To evaluate organ atrophy induced by sorafenib and sunitinib, we retrospectively reviewed the CT scans of renal cell carcinoma (RCC) patients receiving molecular targeted therapy (MTT) using sorafenib or sunitinib, and performed volumetric...Keywords
This publication has 15 references indexed in Scilit:
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid effects of tyrosine kinase inhibitorsEuropean Journal of Endocrinology, 2014
- Pancreatic Atrophy — A New Late Toxic Effect of SorafenibNew England Journal of Medicine, 2013
- Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and FutureSeminars in Oncology, 2013
- Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular CarcinomaThyroid®, 2011
- CT Findings of Chemotherapy-induced Toxicity: What Radiologists Need to Know about the Clinical and Radiologic Manifestations of Chemotherapy ToxicityRadiology, 2011
- The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinomaBritish Journal of Cancer, 2010
- Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled StudyJournal of Clinical Oncology, 2010
- Sorafenib and SunitinibThe Oncologist, 2009
- Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing StrategiesThe Oncologist, 2008
- Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell CarcinomaJapanese Journal of Clinical Oncology, 2007